Cardiovascular Toxicity Assessment In Oncology Trials Workshop
September 22, 2016
Organized by FDA
with support from: AACR, ACC, AHA & ASCO

Speakers and Panelists

Darrell Abernethy, MD, PhD
Associate Director for Drug Safety
Office of Clinical Pharmacology (OCP)
Office of Translational Science (OTS) CDER/FDA
Silver Spring, MD

Laleh Amiri-Kordestani, MD
Clinical Team Leader
Breast/Gynecology Team
Division of Oncology Product 1
Office of Hematology and Oncology Products
CDER/FDA
Silver Spring, MD

Ana Barac, MD, PhD, FACC
Director, Cardio-oncology Program
Medstar Heart Institute
Medical Director
Cardiac Rehabilitation Program
Medstar Washington Hospital Center
Associate Professor of Medicine
Georgetown University
Washington, DC

Paul W. Burridge, PhD
Northwestern University Feinberg School of Medicine
Chicago, IL

Robert Califf, MD, MACC
Commissioner
U.S. Food & Drug Administration
Silver Spring, MD

Kevin J. Croce, MD, PhD
Director, Complex Coronary Artery Intervention Program
Director, Translational Discovery Program
Interventional Cardiology
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Chau T. Dang, MD
Chief, Westchester Medical Oncology Service
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY

R. Angelo de Claro, MD
Clinical Team Leader
Hematology/Benign Hematology Team 4
Office of Hematology and Oncology Products
CDER/FDA
Silver Spring, MD

Michael S. Ewer, MD, MPH, JD
Special Assistant to the Vice President of Medical Affairs
Professor
MD Anderson Cancer Center
University of Texas
Houston, TX

Gary Gintant, PhD
Research Fellow
Dept. Integrative Pharmacology
Integrated Sciences & Technology
AbbVie
North Chicago IL

Juan Carlos Plana Gomez, MD
Chief of Clinical Operations, Cardiology
Department of Medicine,
Baylor College of Medicine
Director of the Cardio-Oncology Center and co-Director, Center for Advanced Cardiac Imaging
Baylor St. Luke's Medical Center
Houston, TX

Nicole Gormley, MD
Clinical Team Leader (Acting)
Hematology/Benign Hematology Team 2
Office of Hematology and Oncology Products
CDER/FDA
Silver Spring, MD

Cardiovascular Toxicity Assessment In Oncology Trials Workshop
September 22, 2016
Organized by FDA
with support from: AACR, ACC, AHA & ASCO

Speakers and Panelists

Benjamin D. Humphreys MD, PhD
Joseph Friedman Associate Professor & Chief
Division of Nephrology
Washington University in St. Louis
School of Medicine
St. Louis, MO

W. Gregory Hundley, MD, FACC, FAHA
Professor
Department of Internal Medicine & Radiology
Wake Forest Baptist Medical Center
Winston-Salem, NC

Bonnie Ky, MD, MSCE
Univ. of Pennsylvania School of Medicine
Asst. Professor of Medicine & Epidemiology
Director, Penn Center for Quantitative Echocardiography
Chair, ECOG Cardiotoxicity Working Group
Philadelphia, PA

Daniel Lenihan, MD
Director, Clinical Research Program,
Professor of Medicine
Vanderbilt Health
Nashville, TN

Steven E. Lipshultz, MD
Department of Pediatrics
Wayne State University School of Medicine
Children's Hospital of Michigan
Detroit, MI

Debra Madden
Advocate/Patient Representative,
FDA Patient Representative,
ECOG/ACRIN Cancer Research Group Patient Representative
PCORI Inaugural Advisory Panel on the Assessment of Prevention, Diagnosis, and Treatment Options,
National Breast Cancer Coalition

Michael Mauro, MD
Hematologist
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering
New York, NY

Myrtle D. Millin, DVM, PhD, Fellow, ATS
Chief, Toxicology and Pharmacology Branch
Developmental Therapeutics Program
Div. of Cancer Treatment and Diagnosis
National Cancer Institute, NIH
Bethesda, MD

Lori Minasian, MD
Deputy Director
NCI/ Division of Cancer Prevention
Bethesda, MD

Javid J. Moslehi, MD
Director, Cardio-Oncology Program
Assistant Professor of Medicine
Vanderbilt School of Medicine
Nashville, Tenn

Babak Navi, MD, MS
AHA Representative
Director, Stroke Center
Assistant Professor of Neurology
Weill Cornell Medical College
New York, NY

Todd Palmby, PhD
Pharmacology/Toxicology Supervisor
Div. of Hematology, Oncology, Toxicology
Office of Hematology and Oncology Products
CDER/FDA
Silver Spring, MD

Thomas Papoian, PhD
Division of Cardiovascular & Renal Products
Office of Drug Evaluation I (ODEI)
CDER/FDA
Silver Spring, MD

Cardiovascular Toxicity Assessment In Oncology Trials Workshop
September 22, 2016
Organized by FDA
with support from: AACR, ACC, AHA & ASCO

Speakers and Panelists

Richard Pazdur, MD
Acting Director
Oncology Center of Excellence (OCE), FDA
Director
Office of Hematology & Oncology Products
CDER, FDA

Sandra M. Swain, MD, FACP, FASCO
Associate Dean for Research Development
Professor of Medicine
Georgetown University Medical Center
Washington, DC

Shari Targum, MD
Clinical Team Leader
Division of Cardiovascular & Renal Products
Office of Drug Evaluation I (ODEI)
CDER/FDA
Silver Spring, MD

Hugo M. Vargas, PhD, DSP
Integrated Discovery & Safety Pharmacology
Comparative Biology and Safety Sciences
Amgen, Inc.
Thousand Oaks, CA

Suparna B. Wedam, MD
Breast Oncology Group
Breast Cancer Scientific Liaison
Division of Oncology Products 1
Office of Hematology & Oncology Products
CDER/FDA
Silver Spring, MD

Neil J. Weissman, MD, FACC, FASE
Director, Cardiovascular Core Laboratories
President, MedStar Health Research Institute
Professor of Medicine,
Georgetown University
Washington, DC